Dave Hallett comes to Recursion after approximately 5 years as the Chief Scientific Officer and Interim CEO of Exscientia. David Hallett, Ph.D., is an experienced “drug hunter” with over 20 years’ track record leading successful teams and driving major strategic collaborations. Prior to joining Exscientia, from 2005 to 2019 he held various positions within Evotec including Executive Vice President of Chemistry and EVP of Alliance Management. Dr. Hallett trained as a medicinal chemist and served as a Research Fellow at Merck & Co., Inc. He holds a B.A. from the University of Cambridge in Natural Sciences, a Ph.D. from the University of Manchester in Synthetic Organic Chemistry and was a post-doctoral fellow in Synthetic Organic Chemistry at the University of Texas Austin.